Lymphopenia is Associated with Severe Coronavirus Disease 2019 (COVID-19) Infections: A Systemic Review and Meta-analysis

Overview

Journal Int J Infect Dis

Publisher Elsevier

Specialty Infectious Diseases

Date 2020 May 8

PMID 32376308

Citations 273

Authors

Qianwen Zhao

Meng Meng

Rahul Kumar

Yinlian Wu

Jiaofeng Huang

Yunlei Deng

Zhiyuan Weng

Li Yang

Affiliations

Soon will be listed here.

Abstract

Objectives: Coronavirus Disease 2019 (COVID-19) is a new respiratory and systemic disease which needs quick identification of potential critical patients. This meta-analysis aimed to explore the relationship between lymphocyte count and the severity of COVID-19.

Methods: A comprehensive systematic literature search was carried out to find studies published from December 2019 to 22 March 2020 from five databases. The language of literatures included English and Chinese. Mean difference (MD) of lymphocyte count in COVID-19 patients with or without severe disease and odds ratio (OR) of lymphopenia for severe form of COVID-19 was evaluated with this meta-analysis.

Results: Overall 13 case-series with a total of 2282 cases were included in the study. The pooled analysis showed that lymphocyte count was significantly lower in severe COVID-19 patients (MD -0.31×10/L; 95%CI: -0.42 to -0.19×10/L). The presence of lymphopenia was associated with nearly threefold increased risk of severe COVID-19 (Random effects model, OR=2.99, 95% CI: 1.31-6.82).

Conclusions: Lymphopenia is a prominent part of severe COVID-19 and a lymphocyte count of less than 1.5×10/L may be useful in predicting the severity clinical outcomes.

Citing Articles

Comparison of Platelet Indices, Lymphocyte, and Systemic Inflammation Indices on Days 1 and 8 in Surviving and Non-Surviving COVID-19 Patients at Hasan Sadikin General Hospital, Bandung, Indonesia.

Harti G, Maulida S, Susandi E, Fadjari T, Sumardi U, Alisjahbana B J Blood Med. 2025; 16:61-74.

PMID: 39926111 PMC: 11806915. DOI: 10.2147/JBM.S499023.

Blood absolute lymphocyte count and trajectory are important in understanding severe COVID-19.

Paules C, Nordwall J, Shaw-Saliba K, Aberg J, Gardner E, Goodman A BMC Infect Dis. 2025; 25(1):67.

PMID: 39810077 PMC: 11734232. DOI: 10.1186/s12879-024-10428-7.

Laboratory findings predictive of critical illness in hospitalized COVID-19 patients in Tunisia.

Belkhir D, Blibech H, Kaabi L, Miladi S, Jebali M, Daghfous J F1000Res. 2024; 13:918.

PMID: 39659435 PMC: 11628936. DOI: 10.12688/f1000research.151333.2.

Immunophenotyping characteristics and clinical outcome of COVID-19 patients treated with azvudine during the Omicron surge.

Qiu M, Song X, Zhang Q, Zou S, Pang L, Nian X Front Immunol. 2024; 15:1465238.

PMID: 39654887 PMC: 11625784. DOI: 10.3389/fimmu.2024.1465238.

Exploring the shared pathogenic mechanisms of tuberculosis and COVID-19: emphasizing the role of VNN1 in severe COVID-19.

Sun P, Wang Y, Zhou S, Liang J, Zhang B, Li P Front Cell Infect Microbiol. 2024; 14:1453466.

PMID: 39639868 PMC: 11618882. DOI: 10.3389/fcimb.2024.1453466.

References

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

Gao Y, Li T, Han M, Li X, Wu D, Xu Y . Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020; 92(7):791-796. PMC: 7228247. DOI: 10.1002/jmv.25770. View

Wu D, Wu T, Liu Q, Yang Z . The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 2020; 94:44-48. PMC: 7102543. DOI: 10.1016/j.ijid.2020.03.004. View

He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G . Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005; 9(6):323-30. PMC: 7110876. DOI: 10.1016/j.ijid.2004.07.014. View

Xie M, Chen Q . Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020; 94:119-124. PMC: 7118633. DOI: 10.1016/j.ijid.2020.03.071. View

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D . Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020; 17(5):533-535. PMC: 7091858. DOI: 10.1038/s41423-020-0402-2. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

Hui D, Azhar E, Madani T, Ntoumi F, Kock R, Dar O . The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020; 91:264-266. PMC: 7128332. DOI: 10.1016/j.ijid.2020.01.009. View

Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G . COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. Clin Exp Rheumatol. 2020; 38(2):337-342. View

10.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

11.

He F, Deng Y, Li W . Coronavirus disease 2019: What we know?. J Med Virol. 2020; 92(7):719-725. PMC: 7228340. DOI: 10.1002/jmv.25766. View

12.

Yang M, Li C, Li K, Hon K, Ng M, Chan P . Hematological findings in SARS patients and possible mechanisms (review). Int J Mol Med. 2004; 14(2):311-5. View

13.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

14.

Wang Z, Yang B, Li Q, Wen L, Zhang R . Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71(15):769-777. PMC: 7184452. DOI: 10.1093/cid/ciaa272. View

15.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

16.

Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt G . A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20):1986-94. DOI: 10.1056/NEJMoa030685. View

17.

Liu W, Tao Z, Wang L, Yuan M, Liu K, Zhou L . Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020; 133(9):1032-1038. PMC: 7147279. DOI: 10.1097/CM9.0000000000000775. View

18.

Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y . Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020; 5(1):33. PMC: 7100419. DOI: 10.1038/s41392-020-0148-4. View

19.

Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N . The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020; 92(10):1915-1921. PMC: 7262275. DOI: 10.1002/jmv.25889. View

20.

Alves da Silva R, de Souza Todao J, Kamitani F, Silva A, de Carvalho-Filho R, Ferraz M . Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. J Med Virol. 2017; 90(3):537-544. DOI: 10.1002/jmv.24976. View